DEFEAT CANCER

NETRIS Pharma is dedicated to defeat cancer through novel and unique approach targeting Netrin-1

Best-in-Class Environment to foster Therapeutic Innovation

NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.

Innovative Therapeutic Approach

By developing therapeutic products targeting a novel mechanism of cancer resistance, we offer patients new solutions alleviating resistance to chemotherapy, targeted therapy and immunotherapy.

Our news

08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

05/16/2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

03/29/2023

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Our publications

08/30/2023

Blockade of netrin-1 is a promising strategy against endometrial cancer - Clinical briefing

08/30/2023

Pharmacological targeting netrin-1 inhibits EMT in cancer

08/30/2023

Netrin-1 blockade inhibits tumor growth and EMT features in endometrial cancer

A Strategic Focus on Intellectual Property Rights

As the world pioneer and leader biopharmaceutical company targeting netrin-1 and ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach.

Our partners

NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate Partners.

Clinical

Corporate

Research